Synthetic Biologics, Inc.
Synthetic Biologics (NYSE MKT: SYN) is developing therapeutics that preserve the microbiome to protect and restore patient health. Our lead programs for PhIII development include a beta-lactamase designed to protect the gut microbiome from residual intravenous antibiotics and a reformulation of lovastatin-lactone designed to reduce methane production in the gut.